Information on the Ring Trial Tumour cytogenetics

Aim

The ring trail aims at the evaluation of the entire process of the chromosome banding analysis in haematological neoplasias starting with the receipt of the sample and ending with the outgoing report.

Performance interval

Once per year.

Procedure

A surrogate blood sample is generated by using cell lines. The sample is sent out with a fictitious request. The request includes a diagnostic question, which needs to be answered by a chromosome banding analysis.

Method

The analysis has to be carried out according to the own laboratory standard operational procedures. For evaluation, the findings have to be submitted in a written diagnostic report.

Criteria

Proof of target aberrations through chromosome banding analysis, correct karyotype, correct report of findings.
The identification of a defined target aberration is prerequisite to attest a successful participation in the ring trial.

Certificate

A certificate will be provided that states the (successful) participation in the trial. The certificate is valid for two years.

Ring trial management

Prof. Dr. med. Harald Rieder
Zytogenetik-Labor Düsseldorf
Postfach 105013 zu Hd. Frau Lenssen Postfach 105013 zu Hd. Frau Lenssen
40041 Düsseldorf
Tel. 0211 811 2350
Fax 0211 811 2538
harald.rieder@uni-duesseldorf.de

Dr. rer. nat. Karin Hardt
Institut für Humangenetik, Universitätsklinikum Düsseldorf
Universitätsstr. 1
40225 Düsseldorf
Tel. +49 211 8 11 50 62
Fax
karin.hardt@hhu.de